Geographic atrophy (GA) patients treated with IZERVAY can reduce the risk of loss of driving eligibility by 41%, according to the latest research.
The results of the study by Astellas Pharma were announced at the recent 2026 Association for Research in Vision and Ophthalmology (ARVO) meeting in Denver, Colorado.
They were from an analysis of phase 3 clinical trials of IZERVAY (avacincaptad pegol) to evaluate its impact on vision loss for people with GA secondary to age-related macular degeneration (AMD)
IZERVAY is one of two treatments for GA now approved for use in Australia.
Its approval by the Therapeutic Goods Administration (TGA) late last year followed consent being issued for Syfovre earlier in 2025.
The latest analysis of the phase 3 trials involved patients eligible to drive at baseline.
Just over 400 people received either IZERVAY or sham.
Analysis of data over two years showed the risk of patients progressing to vision loss bad enough to make them ineligible to drive was 12.6% for those on IZERVAY and 20.1% for the sham group.
That represented a 41% relative risk reduction for those using IZERVAY.
